| 1 |
Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in person with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study |
|
|
| Shravan Venkatraman, Kesavan Ramasamy, Pradeep P. Nair, Priyadharsini Rajendran |
|
| Drug Metabolism and Personalized Therapy. 2023; 0(0) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Pharmacogenetics of carbamazepine adverse drug reactions |
|
|
| V.Yu. Skryabin, M.S. Zastrozhin, E.A. Bryun, D.A. Sychev |
|
| Russian Journal of Pain. 2022; 20(4): 70 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Peculiarities of carbamazepine pharmacogenetics and the most common adverse drug reactions during its use (literature review) |
|
|
| Valentin Yu. Skryabin, Mikhail S. Zastrozhin, Evgeny A. Bryun, Dmitry A. Sychev |
|
| Reviews on Clinical Pharmacology and Drug Therapy. 2022; 20(3): 255 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
?Serum monitoring of carbamazepine in patients with epilepsy and clinical implications |
|
|
| Angel T. Alvarado, Gustavo Paredes, Gregoriana García, Alexis Morales, Ana María Muñoz, María Saravia, Ricardo Losno, María R. Bendezú, Haydee Chávez, Jorge A. García, Mario Pineda, Luis Sullón-Dextre |
|
| Pharmacia. 2022; 69(2): 401 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know? |
|
|
| Ada Man-Choi Ho, Richard M Weinshilboum, Mark A Frye, Joanna M Biernacka |
|
| Pharmacogenomics. 2021; 22(14): 913 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters |
|
|
| Teresa Iannaccone, Carmine Sellitto, Valentina Manzo, Francesca Colucci, Valentina Giudice, Berenice Stefanelli, Antonio Iuliano, Giulio Corrivetti, Amelia Filippelli |
|
| Pharmaceuticals. 2021; 14(3): 204 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
